Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis

International Journal of Rheumatic Diseases

Volumn 15, Issue 4, 2012, Pages 358-365

  Hu, Zaiying ^a   Xu, Manlong ^a   Li, Qiuxia ^a   Lin, Zhiming ^a   Liao, Zetao ^a   Cao, Shuangyan ^a   Wei, Qiujing ^a   Zhang, Yan li ^a   Li, Tianwang ^a   Jin, Ou ^a   Huang, Jianlin ^a   Pan, Yunfeng ^a   Wu, Yuqiong ^a   Deng, Xinghe ^a   Gu, Jieruo ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adalimumab; Ankylosing spondylitis; DKK 1; Fatty deposition; Inflammation

Indexed keywords

ADALIMUMAB; DICKKOPF 1 PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTION INDEX; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FATTY DEPOSITION LESION; FEMALE; HUMAN; INFLAMMATION; LIPID STORAGE; LUMBAR SPINE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SACROILIAC JOINT; SCORING SYSTEM; SPONDYLOARTHRITIS RESEARCH CONSORTIUM OF CANADA MRI INDEX; TREATMENT OUTCOME;

ADIPOSE TISSUE; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JOINTS; LIPID METABOLISM; LUMBAR VERTEBRAE; MALE; QUALITY OF LIFE; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84865297686     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2012.01734.x     Document Type: Article

References (27)

1. Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 18377, 2127-37.
2. Baraliakos X, Listing J, Fritz C et al. (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology (Oxford) 50, 1690-9.
3. Sfikakis PP (2010) The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 11, 180-210.
4. Haibel H, Rudwaleit M, Brandt HC et al. (2006) Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 54, 678-81.
5. Lambert RG, Salonen D, Rahman P et al. (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56, 4005-14.
6. Zochling J, Braun J (2007) Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 21, 699-712.
7. Calin A, Garrett S, Whitelock H et al. (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21, 2281-5.
8. Xu M, Lin Z, Deng X et al. (2011) The Ankylosing Spondylitis Disease Activity Score is a highly discriminatory measure of disease activity and efficacy following tumour necrosis factor-α inhibitor therapies in ankylosing spondylitis and undifferentiated spondyloarthropathies in China. Rheumatology (Oxford) 50, 1466-72.
9. Weber U, Kissling RO, Hodler J (2007) Advances in musculoskeletal imaging and their clinical utility in the early diagnosis of spondyloarthritis. Curr Rheum Rep 9, 353-60.
10. Van der Heijde D, Landewé R, Hermann KG et al. (2007) ASAS/OMERACT MRI in AS Working Group. Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis? J Rheumatol 34, 871-3.
11. Maksymowych W, Pederson SJ, Ostergaard M, Chiowchanwisawakit P, Conner-Spady B, Lambert RGW (2008) Re-appraisal of the chronic MRI Changes in AS by the Canada/Denmark Working Group: validation of the post-inflammatory fat signal. Ann Rheum Dis 67 Suppl. II, 512.
12. Bennett AN, Rehman A, Hensor EM, Marzo-Ortega H, Emery P, McGonagle D (2010) The fatty romanus lesion - A non-inflammatory spinal MRI lesion specific for axial-Spondyloarthropathy. Ann Rheum Dis 69, 891-4.
13. Diarra D, Stolina M, Polzer K et al. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13, 156-63.
14. Uderhardt S, Diarra D, Katzenbeisser J et al. (2010) Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69, 592-7.
15. Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27, 361-8.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21, 2286-91.
17. Maksymowych WP, Inman RD, Salonen D et al. (2005) Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 53, 502-9.
18. Maksymowych WP, Dhillon SS, Park R, Salonen D, Inman RD, Lambert RG (2007) Validation of the Spondyloarthritis Research Consortium of Canada magnetic resonance imaging spinal inflammation index: is it necessary to score the entire spine? Arthritis Rheum 57, 501-7.
19. Maksymowych WP, Inman RD, Salonen D et al. (2005) Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. Arthritis Rheum 53, 703-9.
20. Reed MR, Taylor AL (2008) Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern Med J 38, 781-9.
21. Weber U, Maksymowych WP, Jurik AG et al. (2009) Validation of whole-body against conventional magnetic resonance imaging for scoring acute inflammatory lesions in the sacroiliac joints of patients with spondylarthritis. Arthritis Rheum 61, 893-9.
22. Weber U, Hodler J, Jurik AG et al. (2010) Assessment of active spinal inflammatory changes in patients with axial spondyloarthritis: validation of whole body MRI against conventional MRI. Ann Rheum Dis 69, 648-53.
23. Cruickshank B (1956) Lesions of cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol 71, 73-84.
24. Sieper J, Appel H, Braun J, Rudwaleit M (2008) Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 58, 649-56.
25. Schett G, Zwerina J, David JP (2008) The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 4, 473-80.
26. Maksymowych WP (2009) What do biomarkers tell us about the pathogenesis of ankylosing spondylitis? Arthritis Res Ther 11, 101.
27. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RG (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60, 93-102.